Replies to post #2173 on Keryx Biopharmaceuticals Inc fka KERX

[Ecomike]

This is worth repeating I think:

Really, then why did a major INTERDEPENDENT drug research firm also say the same thing?

Keryx Pharmaceuticals (KERX_) shares fell 22% to $7.11 Friday after an independent research firm raised questions about the company's ability to convince FDA to grant New Chemical Entity status to its experimental iron-based phosphate binder Zerenex.

IPD Analytics, which conducts intellectual property healthcare research for Wall Street investors, issued its Keryx report on Friday. The IPD report also questioned the strength of Keryx's patents protecting Zerenex from potential generic competitors.

You seem to keep ignoring all of the major warning signs here, coming from very credible sources, not just people on small web sites.